

PATENT APPLICATION FEE DETERMINATION RECORD

Effective October 1, 2000

Application or Docket Number

09/963,827
180/124/2

CLAIMS AS FILED - PART I

	(Column 1)	(Column 2)
TOTAL CLAIMS	67	
FOR	NUMBER FILED	NUMBER EXTRA
TOTAL CHARGEABLE CLAIMS	67 minus 20=	47
INDEPENDENT CLAIMS	13 minus 3=	10
MULTIPLE DEPENDENT CLAIM PRESENT <input type="checkbox"/>		

* If the difference in column 1 is less than zero, enter "0" in column 2

CLAIMS AS AMENDED - PART II

7/22/05

	(Column 1)	(Column 2)	(Column 3)
AMENDMENT A	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	67	67	= 0
Independent	5	13	= 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

4/14/06

	(Column 1)	(Column 2)	(Column 3)
AMENDMENT B	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	96	67	= 29
Independent	7	13	= 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

	(Column 1)	(Column 2)	(Column 3)
AMENDMENT C	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total			=
Independent			=
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

- If the entry in column 1 is less than the entry in column 2, write "0" in column 3.
- If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20."
- If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3."
- The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

SMALL ENTITY TYPE ☐

OR OTHER THAN SMALL ENTITY

RATE	FEE
BASIC FEE	355.00
X\$ 9=	423
X40=	400
+135=	
TOTAL	1178.00

RATE	FEE
BASIC FEE	710.00
X\$18=	
X80=	
+270=	
TOTAL	

SMALL ENTITY OR

OTHER THAN SMALL ENTITY

RATE	ADDITIONAL FEE
X\$ 9=	
X40=	
+135=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X80=	
+270=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$ 9=	725
X40=	
+135=	
TOTAL ADDIT. FEE	725

RATE	ADDITIONAL FEE
X\$18=	
X80=	
+270=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$ 9=	
X40=	
+135=	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X\$18=	
X80=	
+270=	
TOTAL ADDIT. FEE	

United States Patent and Trademark Office
- Sales Receipt -

04/12/2006 DWILLIA4 00000001 110980 09963827

01 FC:2202 725.00 DA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/963,827
Applicant: : Sullenger, et al.
Filed : September 26, 2001
TC/A.U. : 1635
Examiner : Sean McGarry

Confirmation No. 1175

Docket No. : 10815.105002
Customer No. : 20786

File only

Mail Stop Amendments
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

March 30, 2006

RESPONSE TO NON-FINAL OFFICE ACTION

Sir:

In response to the Official Action mailed September 30, 2005, please consider the following remarks.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the listing of claims that begins on page 3 of this paper.

Remarks/Arguments begin on page 11 of this paper.

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this Response to Restriction Requirement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

3/30/06
Date


Brent R. Bellows

Specification

Applicants have provided a Substitute Figure 18. In the originally filed Figure 18, several nucleotides in two of the listed sequences was inadvertently misplaced. For the sequence identified as 9-11, a C was inadvertently placed at the first 5' position in the last column labeled S1. The C should be in the column labeled L3.

In the sequence identified as 9-4, an A was inadvertently placed in the last 3' position of the first column labeled S1. The A should be the first 5' position in the column labeled L1. In addition, a U was inadvertently placed at the first 5' position in the last column labeled S1. The U should be in the column labeled L3.

Substitute Figure 18 corrects these misalignments. The Applicants respectfully request that substitute Figure 18 be herewith entered.

Restriction Requirement

Applicants acknowledge the Examiner's rejection of Applicants' grounds of traversal with respect to Group IV.

In the Office Action response of February 2, 2004, Applicants stated that "Suggesting that an experimental setting is a materially different method from the therapeutic use is a suggestion that an *in vitro* model is a wholly different invention from the disease it is modeling... In this case, an *in situ* hybridization is nothing more than a research model of what occurs in the blood stream *in vivo*." Applicants wish to clarify this statement by indicating that the statement was not meant to suggest that methods describing *in vitro* diagnostic applications should be viewed as describing or enabling methods of *in vivo* therapeutic applications. Applicants refer the Examiner to the Office Action response filed on March 23, 2006 in related case 10/155,233 for Applicants' views on this issue.

Applicants believe no further fees are due with this response. Should the Examiner determine otherwise, the Commissioner is hereby authorized to debit any required fee from Deposit Account 11-0980.

Appl. No. 09/963,827
Amdt. dated January 31, 2003
Response to Office Action of October 1, 2003

Respectfully submitted,

Sherry M. Knowles

Sherry M. Knowles
Registration No. 33,052

*w/express permission
of the filer
54,709*

KING & SPALDING
1180 Peachtree Street
Atlanta, Georgia 30309
Telephone: 404-572-3541
Facsimile: 404-572-5134